BR0307479A - Compostos orgânicos - Google Patents

Compostos orgânicos

Info

Publication number
BR0307479A
BR0307479A BR0307479-0A BR0307479A BR0307479A BR 0307479 A BR0307479 A BR 0307479A BR 0307479 A BR0307479 A BR 0307479A BR 0307479 A BR0307479 A BR 0307479A
Authority
BR
Brazil
Prior art keywords
organic compounds
medicament
compound
formula
preparation
Prior art date
Application number
BR0307479-0A
Other languages
English (en)
Inventor
John R Fozard
Eckhard Weber
Hans-J Rgen Pfannkuche
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0307479A publication Critical patent/BR0307479A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)

Abstract

"COMPOSTOS ORGâNICOS". Uso de um composto de fórmula I em forma livre ou na forma de um sal farmaceuticamente aceitável para a preparação de um medicamento para o tratamento de um distúrbio de motilidade funcional das vísceras.
BR0307479-0A 2002-02-08 2003-02-07 Compostos orgânicos BR0307479A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0203061.7A GB0203061D0 (en) 2002-02-08 2002-02-08 Organic compounds
PCT/EP2003/001227 WO2003066062A1 (en) 2002-02-08 2003-02-07 Use of acylaminoalkenylene-amide derivatives in functional motility disorders of the viscera

Publications (1)

Publication Number Publication Date
BR0307479A true BR0307479A (pt) 2004-12-07

Family

ID=9930743

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0307479-0A BR0307479A (pt) 2002-02-08 2003-02-07 Compostos orgânicos

Country Status (19)

Country Link
US (2) US20050203164A1 (pt)
EP (2) EP1476167A1 (pt)
JP (2) JP2005516994A (pt)
KR (2) KR20040081492A (pt)
CN (1) CN1301714C (pt)
AU (1) AU2003244446B2 (pt)
BR (1) BR0307479A (pt)
CA (1) CA2471964A1 (pt)
GB (1) GB0203061D0 (pt)
HK (1) HK1077749A1 (pt)
IL (2) IL162816A0 (pt)
MX (1) MXPA04007640A (pt)
NO (1) NO20043735L (pt)
NZ (1) NZ534231A (pt)
PL (1) PL370255A1 (pt)
RU (1) RU2353356C2 (pt)
TW (1) TWI330177B (pt)
WO (1) WO2003066062A1 (pt)
ZA (1) ZA200404960B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203061D0 (en) * 2002-02-08 2002-03-27 Novartis Ag Organic compounds
CN1874766A (zh) 2003-10-27 2006-12-06 诺瓦提斯公司 神经激肽拮抗剂在尿失禁治疗中的用途
EP2059234B1 (en) 2006-09-08 2011-11-02 Ore Pharmaceuticals Inc. Method for reducing or alleviating inflammation in the digestive tract

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217996A (en) * 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
CZ288345B6 (en) * 1995-02-22 2001-05-16 Novartis Ag Arylacylaminoethanes, process of their preparation and pharmaceutical preparation in which they are comprised
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
GB9525296D0 (en) * 1995-12-11 1996-02-07 Merck Sharp & Dohme Therapeutic agents
MY132550A (en) 1996-08-22 2007-10-31 Novartis Ag Acylaminoalkenylene-amide derivatives as nk1 and nk2 antogonists
GB9708484D0 (en) * 1997-04-25 1997-06-18 Merck Sharp & Dohme Therapeutic agents
TR199903299T2 (xx) * 1997-07-02 2000-07-21 Merck & Co., Inc. Ta�ikinin resept�r antagonisti 2-(R)-(1-(R)- (3,5-Bis(triflorometil) Fenil)Etoksi-3-(S)- (4-Floro)Fenil-4- (3-5(-okso-1H,4H-1,2,4-Triazolo) metilmorfolin'in polimorfik formu.
TW520370B (en) * 1998-11-20 2003-02-11 Meiji Seika Kaisha Benzooxazole derivatives and a pharmaceutical composition containing the derivatives as an active ingredient
GB0010958D0 (en) 2000-05-05 2000-06-28 Novartis Ag Organic compounds
EP1352659A4 (en) * 2000-12-22 2004-06-30 Takeda Chemical Industries Ltd COMBINATION DRUGS
GB0203061D0 (en) * 2002-02-08 2002-03-27 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
JP2005516994A (ja) 2005-06-09
AU2003244446B2 (en) 2006-08-10
EP2216025A3 (en) 2010-11-10
ZA200404960B (en) 2006-05-31
TW200302818A (en) 2003-08-16
NO20043735L (no) 2004-09-07
CN1627947A (zh) 2005-06-15
JP2010241835A (ja) 2010-10-28
HK1077749A1 (en) 2006-02-24
EP2216025A2 (en) 2010-08-11
KR20100100994A (ko) 2010-09-15
US20070293473A1 (en) 2007-12-20
WO2003066062A1 (en) 2003-08-14
PL370255A1 (en) 2005-05-16
TWI330177B (en) 2010-09-11
IL162816A (en) 2010-11-30
KR20040081492A (ko) 2004-09-21
MXPA04007640A (es) 2004-11-10
NZ534231A (en) 2007-02-23
IL162816A0 (en) 2005-11-20
EP1476167A1 (en) 2004-11-17
US20050203164A1 (en) 2005-09-15
RU2353356C2 (ru) 2009-04-27
RU2004127132A (ru) 2005-06-10
GB0203061D0 (en) 2002-03-27
CN1301714C (zh) 2007-02-28
CA2471964A1 (en) 2003-08-14
AU2003244446A1 (en) 2003-09-02

Similar Documents

Publication Publication Date Title
BR0109703A (pt) Derivados de piperazina
BRPI0416628A (pt) uso de compostos orgánicos
IS2517B (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
BR0115910A (pt) Compostos orgânicos
CY1108738T1 (el) Θεραπευτικοι παραγοντες χρησιμοι για την αγωγη του πονου
LU92595I2 (fr) Siméprévir, ou l'un de ses sels pharmaceutiquementacceptables, incluant siméprévir sodium
CY1106697T1 (el) Ν-υποκατεστημενες υδρομορφονες και η χρηση αυτων
BRPI0607545A2 (pt) composto, uso de um composto de fórmula i ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
GEP20094723B (en) Tetraazabenzo [e] azulene derivatives and analogs thereof
CU23260B7 (es) PREPARADO FARMACéUTICO DE MOXIFLOXACINA
BR0315337A (pt) Composto, formulação farmacêutica, e, método para tratar câncer
BRPI0417820A (pt) heterociclos azabicìclicos como moduladores de receptor canabinóide
BRPI0412893A (pt) composto, composição farmacêutica, uso de um composto, e, métodos de prevenção, tratamento ou melhora de doenças ou condições inflamatórias, ou doenças ou condições oftálmicas, de tratamento ou melhora de cáncer e para a produção de um composto
BRPI0407097A (pt) Antagonista do casr
BRPI0518231A2 (pt) derivados de 2-amido-4-feniltiazol, o respectivo preparo e a respectiva aplicaÇço em terapÊutica
BRPI0408295A (pt) uso de um composto
ES2133324T3 (es) Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y metodos de uso.
BRPI0409959A (pt) uso de derivados de azetidinacarboxamida em terapia
PE20010623A1 (es) Uso de (+)-tramadol y/o o-demetiltramadol para tratamiento de urgencia urinaria incrementada y/o incontinencia urinaria
BR0307588A (pt) Composto, inibidor de gsk-3, composição farmacêutica, e, agente terapêutico ou preventivo para uma doença
BRPI0412159A (pt) emprego
DE60112960D1 (de) Kondensierte pyridoindolderivate
PL360492A1 (en) Use of pamoic acid or one of its derivatives, or one of its analogues, for the preparation of a medicament for the treatment of diseases characterised by deposits of amyloid aggregates
SE0101082D0 (sv) Novel use

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 10A E 11A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2258 DE 15/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 10A, 11A, 12A, 13A, 14A, 15A, 16A E 17A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.